Siemens Healthineers Announces FDA Clearance for New PET/CT System at SNMMI Meeting
Emphasizing enhanced time-of-flight performance and an energy-efficient design, the Biograph Trinion PET/CT system can reportedly be utilized for a variety of imaging needs, ranging from theranostic applications to neurology imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Biograph Trinion positron emission tomography/computed tomography (PET/CT) system, which made its debut at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, including oncologic, cardiovascular, and neurologic imaging as well as theranostics, according to Siemens Healthineers, the manufacturer of the Biograph Trinion.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, according to Siemens Healthineers, the manufacturer of the newly FDA-cleared PET/CT system. (Image courtesy of Siemens Healthineers.)
The company emphasized that the device’s computer technology is located in the system gantry, allowing a more compact design that can be accommodated in an existing traditional PET/CT room. Siemens Healthineers added that the system’s smart power-save mode for powering down at night, can lead to a 46 percent reduction in energy costs.
“With the Biograph Trinion, Siemens Healthineers is proud to offer customers a high-performance PET/CT scanner that delivers the precision and speed needed for clinical demands,” said James Williams, PhD, head of Molecular Imaging at Siemens Healthineers. “This new system is designed to be user- and patient focused as well as a sustainable investment in terms of reduced installation and operational costs and easy, on-site scalability.”
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
